HUTCHMED (HCM)

Executive Summary

HUTCHMED is a commercial-stage biopharmaceutical company with a strong focus on oncology, with one approved product (fruquintinib) in multiple geographies and a deep pipeline of 113 drug candidates. The company leverages internal discovery and global partnerships to address significant unmet medical needs. Fruquintinib, approved for metastatic colorectal cancer in the U.S., EU, and China, provides a growing revenue base, while late-stage programs like savolitinib (targeting MET-driven tumors) and sovleplenib (autoimmune) offer substantial upside. With a rich clinical portfolio and commercial capabilities, HUTCHMED is positioned for sustained growth, though near-term profitability is still dependent on successful launches and pipeline progression.

Upcoming Catalysts (preview)

• Q4 2026FDA/EMA decisions on fruquintinib label expansion for other solid tumors (e.g., endometrial cancer)60% success
• Q2 2027Topline Phase 3 data readout for savolitinib in non-small cell lung cancer or renal cell carcinoma55% success
• Q1 2027Potential partnership or licensing deal for overseas rights to sovleplenib or other pipeline assets45% success